{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:06:43Z","timestamp":1791522403728,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Predicting future Alzheimer\u2019s disease (AD)-related cognitive decline among individuals with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) is an important task for healthcare. Structural brain imaging as measured by magnetic resonance imaging (MRI) could potentially contribute when making such predictions. It is unclear if the predictive performance of MRI can be improved using entire brain images in deep learning (DL) models compared to using pre-defined brain regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cohort of 332 individuals with SCD\/MCI were included from the Swedish BioFINDER-1 study. The goal was to predict longitudinal SCD\/MCI-to-AD dementia progression and change in Mini-Mental State Examination (MMSE) over four years. Four models were evaluated using different predictors: (1) clinical data only, including demographics, cognitive tests and\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54 status, (2) clinical data plus hippocampal volume, (3) clinical data plus all regional MRI gray matter volumes (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200968) extracted using FreeSurfer software, (4) a DL model trained using multi-task learning with MRI images, Jacobian determinant images and baseline cognition as input. A double cross-validation scheme, with five test folds and for each of those ten validation folds, was used. External evaluation was performed on part of the ADNI dataset, including 108 patients. Mann-Whitney U-test was used to determine statistically significant differences in performance, with\n                      <jats:italic>p<\/jats:italic>\n                      -values less than 0.05 considered significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the BioFINDER cohort, 109 patients (33%) progressed to AD dementia. The performance of the clinical data model for prediction of progression to AD dementia was area under the curve (AUC)\u2009=\u20090.85 and four-year cognitive decline was R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.14. The performance was improved for both outcomes when adding hippocampal volume (AUC\u2009=\u20090.86, R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.16). Adding FreeSurfer brain regions improved prediction of four-year cognitive decline but not progression to AD (AUC\u2009=\u20090.83, R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.17), while the DL model worsened the performance for both outcomes (AUC\u2009=\u20090.84, R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.08). A sensitivity analysis showed that the Jacobian determinant image was more informative than the MRI image, but that performance was maximized when both were included. In the external evaluation cohort from ADNI, 23 patients (21%) progressed to AD dementia. The results for predicted progression to AD dementia were similar to the results for the BioFINDER test data, while the performance for the cognitive decline was deteriorated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The DL model did not significantly improve the prediction of clinical disease progression in AD, compared to regression models with a single pre-defined brain region.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-024-01428-5","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T02:51:21Z","timestamp":1710816681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer\u2019s disease in patients with mild cognitive symptoms"],"prefix":"10.1186","volume":"16","author":[{"given":"Ida","family":"Arvidsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Tideman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Heyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"\u00c5str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"issue":"6","key":"1428_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"issue":"2","key":"1428_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrneurol.2009.215","volume":"6","author":"GB Frisoni","year":"2010","unstructured":"Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Reviews Neurol. 2010;6(2):67\u201377.","journal-title":"Nat Reviews Neurol"},{"issue":"11","key":"1428_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S1474-4422(19)30353-9","volume":"18","author":"SC Burnham","year":"2019","unstructured":"Burnham SC, Loi SM, Doecke J, Fedyashov V, Dore V, Villemagne VL, Masters CL. The dawn of robust individualised risk models for dementia. Lancet Neurol. 2019;18(11):985\u20137.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1428_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/alz.12638","volume":"18","author":"J Gaugler","year":"2022","unstructured":"Gaugler J, James B, Johnson T, Reimer J, Solis M, Weuve J, et al. 2022 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2022;18(4):700\u201389.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1428_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","volume":"119","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia\u2013meta\u2010analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica. 2009;119(4):252\u201365.","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"1428_CR6","doi-asserted-by":"publisher","first-page":"19853","DOI":"10.1038\/s41598-021-99310-z","volume":"11","author":"A Kumar","year":"2021","unstructured":"Kumar A, Shoai M, Palmqvist S, Stomrud E, Hardy J, Mattsson-Carlgren N, Hansson O. Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer\u2019s disease. Sci Rep. 2021;11(1):19853.","journal-title":"Sci Rep"},{"issue":"6","key":"1428_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"1","key":"1428_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"1428_CR9","doi-asserted-by":"publisher","first-page":"22252","DOI":"10.1038\/s41598-020-79243-9","volume":"10","author":"JB Bae","year":"2020","unstructured":"Bae JB, Lee S, Jung W, Park S, Kim W, Oh H, et al. Identification of Alzheimer\u2019s disease using a convolutional neural network model based on T1-weighted magnetic resonance imaging. Sci Rep. 2020;10(1):22252.","journal-title":"Sci Rep"},{"key":"1428_CR10","doi-asserted-by":"crossref","unstructured":"B\u00e4ckstr\u00f6m K, Nazari M, Gu IY-H, Jakola AS. An efficient 3D deep convolutional network for Alzheimer\u2019s disease diagnosis using MR images. 2018 IEEE 15th International Symposium on Biomedical Imaging (ISBI 2018); 2018: IEEE.","DOI":"10.1109\/ISBI.2018.8363543"},{"key":"1428_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.mri.2021.02.001","volume":"78","author":"J Zhang","year":"2021","unstructured":"Zhang J, Zheng B, Gao A, Feng X, Liang D, Long X. A 3D densely connected convolution neural network with connection-wise attention mechanism for Alzheimer\u2019s disease classification. Magn Reson Imaging. 2021;78:119\u201326.","journal-title":"Magn Reson Imaging"},{"key":"1428_CR12","doi-asserted-by":"publisher","first-page":"101694","DOI":"10.1016\/j.media.2020.101694","volume":"63","author":"J Wen","year":"2020","unstructured":"Wen J, Thibeau-Sutre E, Diaz-Melo M, Samper-Gonz\u00e1lez J, Routier A, Bottani S, et al. Convolutional neural networks for classification of Alzheimer\u2019s disease: overview and reproducible evaluation. Med Image Anal. 2020;63:101694.","journal-title":"Med Image Anal"},{"key":"1428_CR13","doi-asserted-by":"crossref","unstructured":"Ramon-Julvez U, Hernandez M, Mayordomo E. Analysis of the influence of diffeomorphic normalization in the prediction of stable vs progressive MCI conversion with convolutional neural networks. 2020 IEEE 17th International Symposium on Biomedical Imaging (ISBI); 2020: IEEE.","DOI":"10.1109\/ISBI45749.2020.9098445"},{"key":"1428_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.neuroimage.2019.01.031","volume":"189","author":"S Spasov","year":"2019","unstructured":"Spasov S, Passamonti L, Duggento A, Lio P, Toschi N. Alzheimer\u2019s Disease Neuroimaging Initiative. A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer\u2019s disease. NeuroImage. 2019;189:276\u201387.","journal-title":"NeuroImage"},{"key":"1428_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fnins.2020.00259","volume":"14","author":"D Pan","year":"2020","unstructured":"Pan D, Zeng A, Jia L, Huang Y, Frizzell T, Song X. Early detection of Alzheimer\u2019s disease using magnetic resonance imaging: a novel approach combining convolutional neural networks and ensemble learning. Front NeuroSci. 2020;14:259.","journal-title":"Front NeuroSci"},{"key":"1428_CR16","doi-asserted-by":"publisher","first-page":"101850","DOI":"10.1016\/j.media.2020.101850","volume":"67","author":"K Hett","year":"2021","unstructured":"Hett K, Ta V-T, Oguz I, Manj\u00f3n JV, Coup\u00e9 P. Alzheimer\u2019s Disease Neuroimaging Initiative. Multi-scale graph-based grading for Alzheimer\u2019s disease prediction. Med Image Anal. 2021;67:101850.","journal-title":"Med Image Anal"},{"issue":"1","key":"1428_CR17","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41598-020-78095-7","volume":"11","author":"SA Mofrad","year":"2021","unstructured":"Mofrad SA, Lundervold AJ, Vik A, Lundervold AS. Cognitive and MRI trajectories for prediction of Alzheimer\u2019s disease. Sci Rep. 2021;11(1):2122.","journal-title":"Sci Rep"},{"key":"1428_CR18","doi-asserted-by":"publisher","first-page":"e560","DOI":"10.7717\/peerj-cs.560","volume":"7","author":"E Ocasio","year":"2021","unstructured":"Ocasio E, Duong TQ. Deep learning prediction of mild cognitive impairment conversion to Alzheimer\u2019s disease at 3 years after diagnosis using longitudinal and whole-brain 3D MRI. PeerJ Comput Sci. 2021;7:e560.","journal-title":"PeerJ Comput Sci"},{"issue":"1","key":"1428_CR19","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1038\/s41467-022-31037-5","volume":"13","author":"S Qiu","year":"2022","unstructured":"Qiu S, Miller MI, Joshi PS, Lee JC, Xue C, Ni Y, et al. Multimodal deep learning for Alzheimer\u2019s disease dementia assessment. Nat Commun. 2022;13(1):3404.","journal-title":"Nat Commun"},{"key":"1428_CR20","doi-asserted-by":"crossref","unstructured":"Chen X, Tang M, Liu A, Wei X. Diagnostic accuracy study of automated stratification of Alzheimer\u2019s disease and mild cognitive impairment via deep learning based on MRI. Annals of Translational Medicine. 2022;10.14.","DOI":"10.21037\/atm-22-2961"},{"key":"1428_CR21","doi-asserted-by":"publisher","first-page":"876202","DOI":"10.3389\/fnagi.2022.876202","volume":"14","author":"BY Lim","year":"2022","unstructured":"Lim BY, Lai KW, Haiskin K, Kulathilake KA, Ong ZC, Hum YC, et al. Deep learning model for prediction of progressive mild cognitive impairment to Alzheimer\u2019s disease using structural MRI. Front Aging Neurosci. 2022;14:876202.","journal-title":"Front Aging Neurosci"},{"key":"1428_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13195-022-00985-x","volume":"141","author":"X Feng","year":"2022","unstructured":"Feng X, Provenzano FA, Small SA. Alzheimer\u2019s Disease Neuroimaging Initiative. A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;141:45.","journal-title":"Alzheimers Res Ther"},{"key":"1428_CR23","doi-asserted-by":"publisher","first-page":"100091","DOI":"10.1016\/j.ibmed.2023.100091","volume":"7","author":"K de Silva","year":"2023","unstructured":"de Silva K, Kunz H. Prediction of Alzheimer\u2019s disease from magnetic resonance imaging using a convolutional neural network. Intelligence-Based Med. 2023;7:100091.","journal-title":"Intelligence-Based Med"},{"key":"1428_CR24","doi-asserted-by":"crossref","unstructured":"Romano MF, Zhou X, Balachandra AR, Jadick MF, Qiu S, Nijhawan DA et al. Deep learning for risk-based stratification of cognitively impaired individuals. iScience. 2023;26.9.","DOI":"10.1016\/j.isci.2023.107522"},{"key":"1428_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00900-w","volume":"13","author":"S Grueso","year":"2021","unstructured":"Grueso S, Viejo-Sobera R. Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer\u2019s disease dementia: a systematic review. Alzheimers Res Ther. 2021;13:1\u201329.","journal-title":"Alzheimers Res Ther"},{"key":"1428_CR26","doi-asserted-by":"publisher","first-page":"105242","DOI":"10.1016\/j.cmpb.2019.105242","volume":"187","author":"MA Ebrahimighahnavieh","year":"2020","unstructured":"Ebrahimighahnavieh MA, Luo S, Chiong R. Deep learning to detect Alzheimer\u2019s disease from neuroimaging: a systematic literature review. Comput Methods Programs Biomed. 2020;187:105242.","journal-title":"Comput Methods Programs Biomed"},{"issue":"6","key":"1428_CR27","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging Initiative. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034\u201342.","journal-title":"Nat Med"},{"issue":"1","key":"1428_CR28","doi-asserted-by":"publisher","first-page":"10918","DOI":"10.1038\/ncomms10918","volume":"7","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Insel PS, Palmqvist S, Stomrud E, Van Westen D, Minthon L, et al. Increased amyloidogenic APP processing in APOE \u025b4-negative individuals with cerebral \u03b2-amyloidosis. Nat Commun. 2016;7(1):10918.","journal-title":"Nat Commun"},{"issue":"4","key":"1428_CR29","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3233\/JAD-191191","volume":"75","author":"F Petrazzuoli","year":"2020","unstructured":"Petrazzuoli F, Vestberg S, Midl\u00f6v P, Thulesius H, Stomrud E, Palmqvist S. Brief cognitive tests used in primary care cannot accurately differentiate mild cognitive impairment from subjective cognitive decline. J Alzheimers Dis. 2020;75(4):1191\u2013201.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1428_CR30","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.neuroimage.2011.09.015","volume":"62","author":"M Jenkinson","year":"2012","unstructured":"Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. FSL NeuroImage. 2012;62(2):782\u201390.","journal-title":"FSL NeuroImage"},{"key":"1428_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fninf.2014.00044","volume":"8","author":"BB Avants","year":"2014","unstructured":"Avants BB, Tustison NJ, Stauffer M, Song G, Wu B, Gee JC. The insight ToolKit image registration framework. Front Neuroinformatics. 2014;8:44.","journal-title":"Front Neuroinformatics"},{"issue":"4","key":"1428_CR32","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jalz.2018.12.001","volume":"15","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Insel PS, Donohue M, J\u00f6gi J, Ossenkoppele R, Olsson T, et al. Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2019;15(4):570\u201380.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"11","key":"1428_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry. 1984;141(11):1356\u201364.","journal-title":"Am J Psychiatry"},{"key":"1428_CR34","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in Python. J Mach Learn Res. 2011;12:2825\u201330.","journal-title":"J Mach Learn Res"},{"key":"1428_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1023\/A:1007379606734","volume":"28","author":"R Caruana","year":"1997","unstructured":"Caruana R. Multitask learning. Mach Learn. 1997;28:41\u201375.","journal-title":"Mach Learn"},{"key":"1428_CR36","unstructured":"Chollet F, Keras. 2015 [Available from: https:\/\/keras.io, accessed 6 October 2023.]."},{"key":"1428_CR37","unstructured":"Abadi M, Barham P, Chen J, Chen Z, Davis A, Dean J et al. TensorFlow: a system for Large-Scale machine learning. 12th USENIX symposium on operating systems design and implementation (OSDI 16); 2016."},{"key":"1428_CR38","unstructured":"Rieke J, Eitel F, Weygandt M, Haynes J-D, Ritter K. Visualizing convolutional networks for MRI-based diagnosis of Alzheimer\u2019s disease. Understanding and Interpreting Machine Learning in Medical Image Computing Applications: First International Workshops, MLCN 2018, DLF 2018, and iMIMIC 2018, Held in Conjunction with MICCAI 2018, Granada, Spain, September 16\u201320, 2018, Proceedings 1; 2018: Springer."},{"key":"1428_CR39","doi-asserted-by":"crossref","unstructured":"Zeiler MD, Fergus R. Visualizing and understanding convolutional networks. Computer Vision\u2013ECCV. 2014: 13th European Conference, Zurich, Switzerland, September 6\u201312, 2014, Proceedings, Part I 13; 2014: Springer.","DOI":"10.1007\/978-3-319-10590-1_53"},{"issue":"3","key":"1428_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer\u2019s disease neuroimaging initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201\u20139.","journal-title":"Neurology"},{"issue":"8419","key":"1428_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0140-6736(85)90965-1","volume":"325","author":"MJ Ball","year":"1985","unstructured":"Ball MJ, Hachinski V, Fox A, Kirshen AJ, Fisman M, Blume W, et al. A new definition of Alzheimer\u2019s disease: a hippocampal dementia. Lancet. 1985;325(8419):14\u20136.","journal-title":"Lancet"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01428-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01428-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01428-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T02:54:54Z","timestamp":1710816894000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01428-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01428-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3569391\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies were approved by the Ethical Review Authority of Sweden and Region Sk\u00e5ne, and all participants gave written informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy\/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. SP has acquired research support (for the institution) from ki elements \/ ADDF. In the past 2 years, he has received consultancy\/speaker fees from BioArtic, Biogen, Lilly, and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}